Innovent Biologics Inc. (HKG: 1801), based in China, has announced the signing of a clinical study and supply cooperation agreement with ImmVirX Pty Ltd. This strategic partnership will facilitate a clinical study that combines Innovent’s Tyvyt (sintilimab), a programmed death-1 (PD-1) inhibitor already approved in China for seven different indications, with ImmVirX’s oncolytic virus therapeutic candidate, IVX037.
Currently, IVX037 is under investigation in a Phase I clinical study in Australia. Preliminary results from a Phase Ia trial suggest that IVX037 is well tolerated following multiple intratumoral injections. Early findings indicate potential induction of beneficial inflammatory cytokines and chemokines such as CXCL10, along with observed anti-tumor activity in select patients with injected lesions. A Phase Ib study is anticipated to commence in mid-2024, aiming to evaluate the anti-tumor efficacy and tolerability of this combination therapy in patients with advanced colorectal, ovarian, and gastric cancers, with plans to enroll 45 participants. Innovent will provide sintilimab for this multi-center study.- Flcube.com
